Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation
- 1 October 2009
- journal article
- case report
- Published by Springer Science and Business Media LLC in Clinical and Experimental Nephrology
- Vol. 13 (5), 522-525
- https://doi.org/10.1007/s10157-009-0198-y
Abstract
We report a 58-year-old Japanese man with primary systemic AL amyloidosis who achieved disappearance of proteinuria including Bence-Jones protein (lambda-type) after two courses of VAD therapy (vincristine, doxorubicin, and dexamethasone) and subsequent high-dose melphalan, followed by autologous peripheral blood stem cell transplantation. Because this patient did not have any apparent amyloidosis-related heart or liver damage and met all of the eligibility criteria for this therapy, this treatment was performed. Both proteinuria and M-protein disappeared completely, and he is doing well clinically at 19 months after treatment. However, amyloid deposits were still found in the kidneys, including the glomeruli and tubulointerstitium, when renal biopsy was done at 8 months after treatment. In the future, we may reach a time when clinical remission corresponds to histological remission.Keywords
This publication has 10 references indexed in Scilit:
- High-Dose Melphalan versus Melphalan plus Dexamethasone for AL AmyloidosisNew England Journal of Medicine, 2007
- VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selectionAmyloid, 2004
- Nephrotic Syndrome Due to Primary AL Amyloidosis, Successfully Treated with VAD and Subsequent High-dose Melphalan Followed by Autologous Peripheral Blood Stem Cell Transplantation.Internal Medicine, 2003
- Autologous stem cell transplantation for primary systemic amyloidosisBlood, 2002
- The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasoneBritish Journal of Cancer, 1998
- Prognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patientsBritish Journal of Haematology, 1998
- Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.1998
- Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 PatientsBlood, 1998
- A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and ColchicineNew England Journal of Medicine, 1997
- Primary systemic amyloidosis: clinical and laboratory features in 474 cases.1995